(Q38097750)

28 August 2017

Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab (English)

1 reference

28 August 2017

0 references

1 reference

1 reference

1

1 reference

28 August 2017

Luisa Costa

5

0 references

Andrea Doria

object named as

Andrea Doria

7

0 references

Leonardo Punzi

object named as

Leonardo Punzi

6

0 references

author name string

Luca Iaccarino

2

1 reference

28 August 2017

Silvano Bettio

3

1 reference

28 August 2017

Francesca Ometto

4

1 reference

28 August 2017

1 July 2013

1 reference

28 August 2017

1 reference

28 August 2017

56

1 reference

28 August 2017

2-3

1 reference

28 August 2017

390-397

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-013-8411-1

28 August 2017

0 references

cites work

Pemphigus and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Modern diagnosis of autoimmune blistering skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Autoimmune blistering diseases of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Diagnosis and clinical features of pemphigus foliaceus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Concurrence of systemic lupus erythematosus and pemphigus: coincidence or correlation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Systemic lupus erythematosus and pemphigus vulgaris: association or coincidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Pemphigus vulgaris and systemic lupus erythematosus in a 46-y-old man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

A single cycle of rituximab for the treatment of severe pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Efficacy and safety of rituximab treatment in Indian pemphigus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Psoriasiform pemphigus foliaceus: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Quality of life in patients with pemphigus receiving adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Rituximab - shadow, illusion or light?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Rituximab-it was the best of times, it was the worst of times.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Current therapy of the pemphigus group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

New insights into the pathogenesis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Overlap connective tissue disease syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Interleukin-6 as a key player in systemic inflammation and joint destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Autoinflammation and autoimmunity: bridging the divide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Pemphigus autoimmunity: hypotheses and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Regulatory T cells: the suppressor arm of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Therapeutic targeting of the interleukin-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Rheumatoid Arthritis Associated With Pemphigus Foliaceus in a Patient Not Taking Penicillamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8411-1

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Pemphigus vulgaris treated with adalimumab: case study

1 reference

12 December 2020

TNFalpha and IL-6 are mediators in the blistering process of pemphigus

1 reference

12 December 2020

Successful treatment of pemphigus vulgaris with etanercept in four patients

1 reference

12 December 2020

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients

1 reference

12 December 2020

Treatment of retinal vasculitis in Behçet's disease with rituximab

1 reference

12 December 2020

A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment

1 reference

12 December 2020

Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients

1 reference

12 December 2020

Low-dose rituximab is effective in pemphigus

1 reference

12 December 2020

Pemphigus foliaceus in an 11-year-old boy with dermatomyositis: simple coincidence or familial immunological background?

1 reference

12 December 2020

Pemphigus foliaceus treated with etanercept

1 reference

12 December 2020

Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis

1 reference

12 December 2020

Autoimmune diseases in patients with pemphigus and their first-degree relatives

1 reference

12 December 2020

Infliximab in the management of severe pemphigus vulgaris

1 reference

12 December 2020

Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.

1 reference

12 December 2020

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

1 reference

12 December 2020

Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab

1 reference

12 December 2020

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

12 December 2020

Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab

1 reference

12 December 2020

Treatment of severe pemphigus foliaceus with rituximab

1 reference

12 December 2020

Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients

1 reference

12 December 2020

Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up

1 reference

12 December 2020

Th17 cells in Behçet's disease: a new immunoregulatory axis.

1 reference

12 December 2020

Paraneoplastic pemphigus

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Successful treatment of recalcitrant pemphigus foliaceus with rituximab

1 reference

12 December 2020

Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity

1 reference

12 December 2020

Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3

1 reference

12 December 2020

Increased titres of IgM anti-heparan sulfate antibody in Behçet's disease

1 reference

12 December 2020

Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents.

1 reference

12 December 2020

Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus

1 reference

12 December 2020

Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients

1 reference

12 December 2020

Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome

1 reference

12 December 2020

Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients

1 reference

12 December 2020

Dermatomyositis and pemphigus vulgaris: association or coincidence?

1 reference

12 December 2020

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins

1 reference

12 December 2020

Clinical status and optimal use of rituximab for B-cell lymphomas

1 reference

12 December 2020

10.1007/S12026-013-8411-1

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference